<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="4-part\PMC7273724\results\search\disease\results.xml">
  <result pre="with these terms. Abstract Cross-subtype neutralizing single domain antibodies against" exact="influenza" post="present new opportunities for immunoprophylaxis and pandemic preparedness. Their"/>
  <result pre="cross-subtype neutralization in vitro of H1N1, H5N1, H2N2, and H9N2" exact="influenza" post="viruses, through binding to a highly conserved epitope in"/>
  <result pre="viruses, through binding to a highly conserved epitope in the" exact="influenza" post="hemagglutinin stem region. To evaluate the potential of R1a-B6"/>
  <result pre="protection against lethal challenge with both pandemic A/California/07/2009 (H1N1)pdm09 and" exact="avian influenza" post="A/Vietnam/1194/2004 (H5N1). This data suggests that R1a-B6 is capable"/>
  <result pre="against lethal challenge with both pandemic A/California/07/2009 (H1N1)pdm09 and avian" exact="influenza" post="A/Vietnam/1194/2004 (H5N1). This data suggests that R1a-B6 is capable"/>
  <result pre="cross-subtype neutralizing nanobodies may be an effective strategy to prevent" exact="influenza" post="infection and provide long-term protection independent of a host"/>
  <result pre="provide long-term protection independent of a host induced immune response." exact="influenza" post="vaccine adeno associated viral vectors immunoprophylaxis immunotherapy nanobody monoclonal"/>
  <result pre="epidemics and occasional pandemics (1). In a pandemic, a new" exact="influenza" post="virus emerges and infects the human population which has"/>
  <result pre="the virus their effectiveness is limited in treating patients with" exact="influenza" post="(5, 6). There is clearly an urgent need for"/>
  <result pre="promising strategy is to use recombinant monoclonal antibodies (mAbs) against" exact="influenza" post="and several are currently in clinical development (9–13). These"/>
  <result pre="already been shown as a viable approach to protect from" exact="influenza" post="(20, 21). The intramuscular injection of AAV8 expressing the"/>
  <result pre="mAb F10 could protect young, old, and immunocompromised mice from" exact="influenza" post="challenge through sustained expression in the systemic circulation for"/>
  <result pre="which was shown to protect mice and ferrets from lethal" exact="influenza" post="challenge. In this study FI6 was delivered intranasally which"/>
  <result pre="may be beneficial as this is the natural site of" exact="influenza" post="infection (22, 23). Despite these findings, significant challenges remain"/>
  <result pre="analysis of several of the earliest human mAbs against the" exact="influenza" post="HA stem revealed the unusual feature that they employ"/>
  <result pre="be products of an immediate and sub-optimal immune response to" exact="influenza" post="(26, 27). This prompted our interest in naturally occurring"/>
  <result pre="of high affinity broadly neutralizing single domain antibodies (nanobodies) against" exact="influenza" post="A and B (28, 29). This antibody format is"/>
  <result pre="due to the alpaca’s limited immune history of exposure to" exact="influenza" post="(31). Nanobodies have several well-described advantages over conventional mAbs"/>
  <result pre="over conventional mAbs which make them ideal for applications in" exact="infectious disease" post="(32–34). One interesting feature is that they have a"/>
  <result pre="capable of cross subtype neutralization of pandemic A(H1N1)2009, highly pathogenic" exact="avian influenza" post="H5N1, H2N2 and H9N2 (28, 40). R1a-B6 neutralizes influenza"/>
  <result pre="of cross subtype neutralization of pandemic A(H1N1)2009, highly pathogenic avian" exact="influenza" post="H5N1, H2N2 and H9N2 (28, 40). R1a-B6 neutralizes influenza"/>
  <result pre="avian influenza H5N1, H2N2 and H9N2 (28, 40). R1a-B6 neutralizes" exact="influenza" post="through binding to a highly conserved epitope in the"/>
  <result pre="is required for efficacy of human mAbs specific for the" exact="influenza" post="HA stem (45, 46). Recent studies by Laursen and"/>
  <result pre="and colleagues have also described cross-neutralizing single domain antibodies to" exact="influenza" post="and furthermore shown in vivo efficacy by intranasal AAV"/>
  <result pre="epitopes on HA to provide almost complete protection against both" exact="influenza" post="A and B virus in mouse challenge models. Our"/>
  <result pre="shown to be effective in mice against HIV (50) and" exact="influenza" post="(20). AAV8 and AAV9 share the same tropism, however,"/>
  <result pre="R1a-B6 to accomplish long term, safe, broad protection from pandemic" exact="influenza" post="in vulnerable patient groups. Materials and Methods Nanobody-Fc Expression"/>
  <result pre="of Nanobody-Fc via ELISA The nanobody-Fc constructs were tested against" exact="influenza" post="antigen standards from the National Institute for Biological Standards"/>
  <result pre="Plates were coated overnight with 50 μL/well of 5 μg/mL" exact="influenza" post="virus antigen standard diluted in PBS at 4°C. Serial"/>
  <result pre="G7513) was prepared. For TCID50 determination, a 10–4 dilution of" exact="influenza" post="virus was made and diluted ten-fold across the plate."/>
  <result pre="group, were added and culled 3-days post-challenge, to quantify residual" exact="influenza" post="in the lungs and for histological analysis. Hemagglutination Inhibition"/>
  <result pre="then shown to bind to a broad panel of whole" exact="influenza" post="virus reference reagents (Figure 1E and Supplementary Figure 1)"/>
  <result pre="the breadth of neutralizing activity to include the more divergent" exact="influenza" post="subtype A(H2N2) rather than increasing maximum levels of potency"/>
  <result pre="triplicate. (E) Binding of R1a-B6 against a broad range of" exact="influenza" post="A subtypes as tested by ELISA. Half maximal effective"/>
  <result pre="expressed as the reciprocal of the highest dilution at which" exact="influenza" post="infection is completely blocked. Mice given R1a-B6 (all doses)"/>
  <result pre="of R1a-B6 present in mouse sera would react with other" exact="influenza" post="strains belonging to key influenza subtypes. We obtained mouse"/>
  <result pre="sera would react with other influenza strains belonging to key" exact="influenza" post="subtypes. We obtained mouse sera 6-weeks post AAV IM"/>
  <result pre="These mice were naïve and had not been exposed to" exact="influenza" post="so immunoreactivity to heterologous strains can be attributed solely"/>
  <result pre="monovalent R1a-B6 showed lower reactivity against the panel of whole" exact="influenza" post="virus antigen standards (Figure 3C), which was consistent with"/>
  <result pre="and those given PBS did not show any reactivity against" exact="influenza" post="virus (data not shown). In addition to cross-subtype specificity,"/>
  <result pre="vg AAV encoding nanobodies. (A–C) Binding of R1a-B6 against different" exact="influenza" post="subtypes was tested via ELISA. Plates were coated with"/>
  <result pre="was tested via ELISA. Plates were coated with 5 μg/mL" exact="influenza" post="reference reagent (Supplementary Table 3) and the Absorbance at"/>
  <result pre="(B/BR/08) served as negative controls. (D)In vitro neutralization against different" exact="influenza" post="pseudotypes was determined via a luciferase-reporter assay and given"/>
  <result pre="whether AAV delivery of R1a-B6 transgenes protects mice from lethal" exact="influenza" post="infection, we injected 1 × 1011 vg AAV encoding"/>
  <result pre="confirmation of transgene expression in mouse sera, we proceeded with" exact="influenza" post="challenge via intranasal delivery of 21 MLD50 (mouse lethal"/>
  <result pre="days after AAV administration. Weight loss and clinical symptoms of" exact="influenza" post="were observed for the 14-day study window or until"/>
  <result pre="specific nanobody cAb1-mIgG2a and those given PBS showed symptoms of" exact="influenza" post="including difficulty in breathing, pinched waists and sunken abdomen"/>
  <result pre="In contrast, there was no weight loss or symptoms of" exact="influenza" post="infection observed in mice given R1a-B6-mIgG1 and R1a-B6-mIgG2a (n"/>
  <result pre="for the duration of the study demonstrating complete protection from" exact="influenza" post="(Figures 4B,C and Supplementary Figure 2). Mice given monovalent"/>
  <result pre="Mice given monovalent R1a-B6 without mouse Fc, showed symptoms of" exact="influenza" post="infection 6 days post-challenge, which was a delay of"/>
  <result pre="R1a-B6-mIgG2a, the latter two groups being mice that survived the" exact="influenza" post="challenge with no observable symptoms of infection. We concluded"/>
  <result pre="with no observable symptoms of infection. We concluded that after" exact="influenza" post="challenge, both infection-induced anti-head HA antibodies and anti-stem R1a-B6"/>
  <result pre="the prophylactic efficacy of R1a-B6 can extend to a different" exact="influenza" post="subtype, we tested in an H5N1 influenza challenge model."/>
  <result pre="to a different influenza subtype, we tested in an H5N1" exact="influenza" post="challenge model. The study design was the same as"/>
  <result pre="of a re-assortant virus derived from A/Vietnam/1194/04 (H5N1). Symptoms of" exact="influenza" post="and rapid weight loss were observed 2-days post-challenge in"/>
  <result pre="R1a-B6-mIgG2a (n = 16) did not show any symptoms of" exact="influenza" post="or any appreciable weight loss for the 13 days"/>
  <result pre="having no viral load (Figure 5E), indicating full protection from" exact="influenza" post="infection. In contrast, mice expressing R1a-B6, cAb1-mIgG2a, and those"/>
  <result pre="alveolar space (Figure 5E). Discussion Vaccination is the mainstay of" exact="influenza" post="infection control, however, high-risk patient groups such as the"/>
  <result pre="patient’s immune system and the prior availability of the matching" exact="influenza" post="strain (63, 64). One approach, which is of considerable"/>
  <result pre="broadly neutralizing monoclonal antibodies which bind to conserved epitopes on" exact="influenza" post="HA (10, 13, 20, 65–67). We have previously described"/>
  <result pre="mice by R1a-B6-Fc fusion in challenge models covering two different" exact="influenza" post="subtypes of pandemic potential. The mice that survived had"/>
  <result pre="stem have been described as utilizing additional mechanisms to neutralize" exact="influenza" post="virus in vivo through recruitment of the effector arm"/>
  <result pre="For instance, HA stem-binding antibodies have been reported to neutralize" exact="influenza" post="virus by binding HA on virally infected cells and"/>
  <result pre="mitigates some of the concerns of antibody dependent enhancement of" exact="influenza" post="(71–73) mediated by interactions with the effector arm of"/>
  <result pre="is not essential for R1a-B6 to provide sufficient protection against" exact="influenza" post="opens up new opportunities for designing an optimized transgene"/>
  <result pre="is an attractive approach to confer broad-based protection against important" exact="influenza" post="subtypes (77) which can enhance preparedness against future potential"/>
  <result pre="influenza subtypes (77) which can enhance preparedness against future potential" exact="influenza" post="pandemics. In addition, our data suggest that the potency"/>
  <result pre="functions to HA binding for neutralization of influenza. Highly pathogenic" exact="avian influenza" post="H5N1, as well as viruses of subtype H2N2 and"/>
  <result pre="to HA binding for neutralization of influenza. Highly pathogenic avian" exact="influenza" post="H5N1, as well as viruses of subtype H2N2 and"/>
  <result pre="AAV mediated gene therapy with highly potent cross-neutralizing nanobodies against" exact="influenza" post="to provide broad protection independent of the prior availability"/>
  <result pre="provide broad protection independent of the prior availability of the" exact="influenza" post="strain and the need for a natural host induced"/>
  <result pre="qualified researcher. Ethics Statement The animal studies using AAV and" exact="influenza" post="challenge were reviewed and approved under Home Office Licenses:"/>
  <result pre="Health Organization (2018). 4.FinebergHV.Pandemic preparedness and response–lessons from the H1N1" exact="influenza" post="of 2009.N Engl J Med. (2014) 370:1335–42.24693893 5.collab: Centers"/>
  <result pre="Centers for Disease Control and Prevention (2017). 6.HaydenFG.Antiviral resistance in" exact="influenza" post="viruses — implications for management and pandemic response.N Engl"/>
  <result pre="J Med. (2006) 354:785–8.16495389 7.LukeTCKilbaneEMJacksonJLHoffmanSL.Meta-analysis: convalescent blood products for Spanish" exact="influenza" post="pneumonia: a future H5N1 treatment?Ann Intern Med. (2006) 145:599–609."/>
  <result pre="Intern Med. (2006) 145:599–609. 16940336 8.ZhouBZhongNGuanY.Treatment with convalescent plasma for" exact="influenza" post="A (H5N1) infection.N Engl J Med. (2007) 357:1450–1.17914053 9.SparrowEFriedeMSheikhMTorvaldsenSNewallAT.Passive"/>
  <result pre="(H5N1) infection.N Engl J Med. (2007) 357:1450–1.17914053 9.SparrowEFriedeMSheikhMTorvaldsenSNewallAT.Passive immunization for" exact="influenza" post="through antibody therapies, a review of the pipeline, challenges"/>
  <result pre="and functional bases for broad-spectrum neutralization of avian and human" exact="influenza" post="a viruses.Nat Struct Mol Biol. (2009) 16:265–73. 10.1038/nsmb.156619234466 11.ThrosbyMvan"/>
  <result pre="cells.PLoS One. (2008) 3:e3942. 10.1371/journal.pone.000394219079604 12.BerryCM.Antibody immunoprophylaxis and immunotherapy for" exact="influenza" post="virus infection: utilization of monoclonal or polyclonal antibodies?Hum Vaccin"/>
  <result pre="Immunother. (2018) 14:796–9.28854120 13.EkiertDBhabhaGElsligerMAFriesenRHJongeneelenMThrosbyMet al.Antibody recognition of a highly conserved" exact="influenza" post="virus epitope.Science. (2009) 324:246–51.19251591 14.WarnockJDaigreCAl-RubeaiM.Viral vectors for gene therapy.Methods"/>
  <result pre="vector for gene therapy.BioDrugs. (2017) 31:317–34. 10.1007/s40259-017-0234-528669112 20.BalazsABBloomJDHongCMRaoDSBaltimoreD.Broad protection against" exact="influenza" post="infection by vectored immunoprophylaxis in mice.Nat Biotechnol. (2013) 31:647–52."/>
  <result pre="FI6 in mouse airway provides partial protection against a new" exact="avian influenza" post="A virus, H7N9.Clin Vaccine Immunol. (2013) 20:1836–7.24132603 24.KashyapASteelJOnerADillonMSwaleRWallKet al.Combinatorial"/>
  <result pre="in mouse airway provides partial protection against a new avian" exact="influenza" post="A virus, H7N9.Clin Vaccine Immunol. (2013) 20:1836–7.24132603 24.KashyapASteelJOnerADillonMSwaleRWallKet al.Combinatorial"/>
  <result pre="24.KashyapASteelJOnerADillonMSwaleRWallKet al.Combinatorial antibody libraries from survivors of the Turkish H5N1" exact="avian influenza" post="outbreak reveal virus neutralization strategies.Proc Natl Acad Sci USA."/>
  <result pre="al.Combinatorial antibody libraries from survivors of the Turkish H5N1 avian" exact="influenza" post="outbreak reveal virus neutralization strategies.Proc Natl Acad Sci USA."/>
  <result pre="Acad Sci USA. (2008) 105:5986–91. 10.1073/pnas.080136710518413603 25.LangSXieJZhuXWuNLernerRWilsonI.Antibody 27F3 broadly targets" exact="influenza" post="A group 1 and 2 hemagglutinins through a further"/>
  <result pre="cross sub-type neutralisation activity of a single domain antibody to" exact="influenza" post="hemagglutinin can be increased by antibody valency.PLoS One. (2014)"/>
  <result pre="9:e103294. 10.1371/journal.pone.010329425084445 29.RamageWGaiottoTBallCRisleyPCarnellGWTempertonNet al.Cross-reactive and lineage-specific single domain antibodies against" exact="influenza" post="B hemagglutinin.Antibodies. (2019) 8:14. 10.3390/antib801001431544820 30.MuyldermansSAtarhouchTSaldanhaJBarbosaJARGHamersR.Sequence and structure of"/>
  <result pre="neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against" exact="influenza" post="virus in vivo.Nat Med. (2014) 20:143–51. 10.1038/nm.344324412922 47.LaursenNFriesenRHZhuXJongeneelenMBloklandSVermondJet al.Universal"/>
  <result pre="in vivo.Nat Med. (2014) 20:143–51. 10.1038/nm.344324412922 47.LaursenNFriesenRHZhuXJongeneelenMBloklandSVermondJet al.Universal protection against" exact="influenza" post="infection by a multidomain antibody to influenza hemagglutinin.Science. (2018)"/>
  <result pre="al.Universal protection against influenza infection by a multidomain antibody to" exact="influenza" post="hemagglutinin.Science. (2018) 362:598–602. 10.1126/science.aaq062030385580 48.WangDZhongLNahidMAGaoG.The potential of adeno-associated viral"/>
  <result pre="vectors vaccines against infectious diseases.Front Immunol. (2014) 5:5. 10.3389/fimmu.2014.0000524478774 65.CortiDCameroniEGuarinoBKallewaardNLZhuQLanzavecchiaA.Tackling" exact="influenza" post="with broadly neutralizing antibodies.Curr Opin Virol. (2017) 24:60–9. 10.1016/j.coviro.2017.03.00228527859"/>
  <result pre="airway expression of antibody protects old and immunodeficient mice against" exact="influenza" post="virus.Clin Vaccine Immunol. (2014) 21:1528–33. 10.1128/CVI.00572-1425209558 69.JegaskandaS.The potential role"/>
  <result pre="role of Fc-receptor functions in the development of a universal" exact="influenza" post="vaccine.Vaccines (Basel). (2018) 6:27. 10.3390/vaccines602002729772781 70.JegaskandaSVandervenHAWheatleyAKKentSJ.Fc or not Fc;"/>
  <result pre="is the question: antibody Fc-receptor interactions are key to universal" exact="influenza" post="vaccine design.Hum Vaccin Immunother. (2017) 13:1–9. 10.1080/21645515.2017.129001828332900 71.KhuranaSLovingCManischewitzJKingLGaugerPHenningsonJet al.Vaccine-induced"/>
  <result pre="10.1080/21645515.2017.129001828332900 71.KhuranaSLovingCManischewitzJKingLGaugerPHenningsonJet al.Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance" exact="influenza" post="virus respiratory disease.Sci Transl Med. (2013) 5:200ra114. 10.1126/scitranslmed.300636623986398 72.RamakrishnanBViswanathanKTharakaramanKDancikVRamanRBabcockGJet"/>
  <result pre="(2016) 24:933–43. 10.1016/j.tim.2016.09.00327751627 73.SkowronskiDMDe SerresGCrowcroftNSJanjuaNZBoulianneNHottesTSet al.Association between the 2008-09 seasonal" exact="influenza" post="vaccine and pandemic H1N1 illness during spring-summer 2009: four"/>
 </snippets>
</snippetsTree>
